112 related articles for article (PubMed ID: 12639818)
1. Gallium arsenide exposure impairs splenic B cell accessory function.
Gondre-Lewis TA; Hartmann CB; Caffrey RE; McCoy KL
Int Immunopharmacol; 2003 Mar; 3(3):403-15. PubMed ID: 12639818
[TBL] [Abstract][Full Text] [Related]
2. Gallium arsenide modulates proteolytic cathepsin activities and antigen processing by macrophages.
Lewis TA; Hartmann CB; McCoy KL
J Immunol; 1998 Sep; 161(5):2151-7. PubMed ID: 9725206
[TBL] [Abstract][Full Text] [Related]
3. Gallium arsenide exposure impairs processing of particulate antigen by macrophages: modification of the antigen reverses the functional defect.
Hartmann CB; McCoy KL
Life Sci; 2004 Jun; 75(4):485-98. PubMed ID: 15147834
[TBL] [Abstract][Full Text] [Related]
4. Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.
Lewis TA; Munson AE; McCoy KL
J Pharmacol Exp Ther; 1996 Sep; 278(3):1244-51. PubMed ID: 8819508
[TBL] [Abstract][Full Text] [Related]
5. Suppression of splenic accessory cell function in mice exposed to gallium arsenide.
Sikorski EE; Burns LA; McCoy KL; Stern M; Munson AE
Toxicol Appl Pharmacol; 1991 Aug; 110(1):143-56. PubMed ID: 1714636
[TBL] [Abstract][Full Text] [Related]
6. Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation.
Hartmann CB; McCoy KL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):365-72. PubMed ID: 8975760
[TBL] [Abstract][Full Text] [Related]
7. Impact of in vitro gallium arsenide exposure on macrophages.
Harrison MT; Hartmann CB; McCoy KL
Toxicol Appl Pharmacol; 2003 Jan; 186(1):18-27. PubMed ID: 12583989
[TBL] [Abstract][Full Text] [Related]
8. Direct exposure to gallium arsenide upregulates costimulatory activity of murine macrophages.
Caffrey-Nolan RE; McCoy KL
Toxicol Appl Pharmacol; 1998 Aug; 151(2):330-9. PubMed ID: 9707509
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxicity of gallium arsenide on antigen presentation: comparative study of intratracheal and intraperitoneal exposure routes.
Hartmann CB; Harrison MT; McCoy KL
J Immunotoxicol; 2005 Jan; 2(1):1-9. PubMed ID: 18958654
[TBL] [Abstract][Full Text] [Related]
10. Splenic cell targets in gallium arsenide-induced suppression of the primary antibody response.
Sikorski EE; Burns LA; Stern ML; Luster MI; Munson AE
Toxicol Appl Pharmacol; 1991 Aug; 110(1):129-42. PubMed ID: 1871769
[TBL] [Abstract][Full Text] [Related]
11. Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55).
Burns LA; Munson AE
J Pharmacol Exp Ther; 1993 Apr; 265(1):178-86. PubMed ID: 8097242
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice.
Sikorski EE; McCay JA; White KL; Bradley SG; Munson AE
Fundam Appl Toxicol; 1989 Nov; 13(4):843-58. PubMed ID: 2695379
[TBL] [Abstract][Full Text] [Related]
13. Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells.
Snider DP; Segal DM
J Immunol; 1989 Jul; 143(1):59-65. PubMed ID: 2471743
[TBL] [Abstract][Full Text] [Related]
14. Gallium arsenide selectively up-regulates inflammatory cytokine expression at exposure site.
Becker SM; McCoy KL
J Pharmacol Exp Ther; 2003 Dec; 307(3):1045-53. PubMed ID: 14560044
[TBL] [Abstract][Full Text] [Related]
15. Gallium arsenide differentially affects processing of phagolysosomal targeted antigen by macrophages.
Lewis TA; Hartmann CB; McCoy KL
J Leukoc Biol; 1998 Mar; 63(3):321-30. PubMed ID: 9500519
[TBL] [Abstract][Full Text] [Related]
16. DNA-mediated transfer of major histocompatibility class II I-Ab and I-Abm12 genes into B lymphoma cells: molecular and functional analysis of introduced antigens.
Ben-Nun A; Choi E; McIntyre KR; Leeman SA; McKean DJ; Seidman JG; Glimcher LH
J Immunol; 1985 Aug; 135(2):1456-64. PubMed ID: 3925010
[TBL] [Abstract][Full Text] [Related]
17. Evidence for arsenic as the immunosuppressive component of gallium arsenide.
Burns LA; Sikorski EE; Saady JJ; Munson AE
Toxicol Appl Pharmacol; 1991 Aug; 110(1):157-69. PubMed ID: 1651571
[TBL] [Abstract][Full Text] [Related]
18. Reversal of gallium arsenide-induced suppression of the antibody-forming cell response by vehicle supernatants. I. Pharmacokinetics after in vitro and in vivo exposure.
Burns LA; Munson AE
J Pharmacol Exp Ther; 1993 Apr; 265(1):144-9. PubMed ID: 8386233
[TBL] [Abstract][Full Text] [Related]
19. Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells.
Lemaire G; Guittet O; Vesin MF; Lepoivre M; Cottet MH
Mol Immunol; 2009 Mar; 46(6):1100-8. PubMed ID: 19095306
[TBL] [Abstract][Full Text] [Related]
20. A mutant antigen-presenting cell defective in antigen presentation expresses class II MHC molecules with an altered conformation.
Dang LH; Lien LL; Benacerraf B; Rock KL
J Immunol; 1993 May; 150(10):4206-17. PubMed ID: 8482833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
